TriSalus Life Sciences Inc（TLSI）のニュースとイベントTLSITriSalus Life Sciences Inc

Major Averages Close Lower as 10-Year Treasury Yield Hits 5.13%

The major averages closed broadly lower as U.S. bond yields jumped to their highest levels in nearly two decades. The 10-year Treasury yield jumped 0.17 percentage point to 5.13%, its highest level since July 2007, as oil prices jumped back above $100 and a monthly S&P survey showed rising private-sector business activity and price pressures. Later in the morning, yields continued their move higher when Fed governor Michael Barr said he expects the central bank will need to raise interest rates further to tamp down inflation.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:Royal Caribbeanagreed to acquire a 50% stake in Sandals for $3BMcDonald'slaunched its new NEXT strategy, introducing new financial targets including aiming for a 1.5 percentage point market share gain in chicken and drinksCracker Barrelreported better-than-expected Q4 earnings and revenue and provided FY27 revenue guidanceGeneral Millsreported upbeat Q1 results and reaffirmed its FY27 guidancePolitico reported that the Trump administration is preparing a 90-day diesel exports ban, though a White House official told Reuters that the report was "fake news"2. WALL STREET CALLS:Microsoftupgraded to Buy at Stifel on revenue growth, efficienciesUBS downgraded PG&Eon risk of inaction on wildfire reformGraphic Packagingupgraded to Overweight at JPMorganCompass Therapeuticsdowngraded at Wedbush and LifeSci Capital as FDA throws wrench in tovecimig plansUBS initiated coverage on five data center stocks with Buy ratings3. AROUND THE WEB:Paramount Skydanceis considering asking Teslafounder Elon Musk for an equity investment as it absorbs Warner Bros. Discovery, Semafor reportsJana Partners is urging Six Flagsto explore a sale, WSJ reportsBayerhas agreed to sell the rights to its cancer drug Stivarga to Gruenenthal Group for up to EUR 375M, or $431M, WSJ reportsMetais testing a "human concierge" for Muse, its new personal AI assistant, which involves having human contractors handle some calls placed via the agent, Reuters saysSpaceXAI'sGrok Bot AI agent has reached over 400,000 weekly users within a month of launching, Bloomberg says4. MOVERS:TriSalus Life Sciencesgains after receiving FDA clearance for TriNav AdvanceNNincreases after raising its outlook for FY26IonQhigher after the company said it successfully tested the first real-time quantum error decoderVoyager Technologiesfalls after offering to sell $350M in senior notesInnovAgedeclines after announcing a 10M share offering5. EARNINGS/GUIDANCE:Espeyreported Q4 results, with EPS and revenue lower year-over-yearPaychexreported Q1 results and provided guidance for FY27Alkamireaffirmed its outlook for FY26Guardforce AIreported results for 1H of FY26Cintasreported Q1 results and raised its outlook for FY27INDEXES:The Dow fell 352.10, or 0.68%, to 51,511.59, the Nasdaq lost 308.24, or 1.13%, to 26,936.04, and the S&P 500 declined 58.61, or 0.75%, to 7,706.03.

Major Averages Broadly Lower as Oil Rises Over 1%

The major averages were broadly lower near noon as Treasury yields rose amid concerns among traders that the Federal Reserve may have more interest rate hikes on the way. Utilities, consumer discretionary, and communication services stocks lead the broader market declines. Meanwhile, oil was up more than 1% amid uncertainty over the U.S.-Iran conflict, with investors balancing supply risks against renewed diplomatic contacts after President Trump said the two sides had held talks at the UN General Assembly.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:Royal Caribbeanagreed to acquire a 50% stake in Sandals for $3BMcDonald'slaunched its new NEXT strategy, introducing new financial targets including aiming for a 1.5 percentage point market share gain in chicken and drinksCracker Barrelreported better-than-expected Q4 earnings and revenue and provided FY27 revenue guidanceGeneral Millsreported upbeat Q1 results and reaffirmed its FY27 guidanceJana Partners is urging Six Flagsto explore a sale, WSJ reports2. WALL STREET CALLS:Microsoftupgraded to Buy at Stifel on revenue growth, efficienciesUBS downgraded PG&Eon risk of inaction on wildfire reformGraphic Packagingupgraded to Overweight at JPMorganCompass Therapeuticsdowngraded at Wedbush and LifeSci Capital as FDA throws wrench in tovecimig plansUBS initiated coverage on five data center stocks with Buy ratings3. AROUND THE WEB:Bayerhas agreed to sell the rights to its cancer drug Stivarga to Gruenenthal Group for up to EUR 375M, or $431M, WSJ reportsMetais testing a "human concierge" for Muse, its new personal AI assistant, which involves having human contractors handle some calls placed via the agent, Reuters saysNovois open to upgrading its New York listing to boost its profile in the U.S., following a similar move by AstraZenecaearlier in the year, FT reportsSpaceXAI'sGrok Bot AI agent has reached over 400,000 weekly users within a month of launching, Bloomberg saysBroadcomfaces rising China risk as authorities survey its switch deployments across state-backed data centers and may push for reduced reliance on its hardware under the "domestic chips for domestic use" campaign, FT says4. MOVERS:TriSalus Life Sciencesgains after receiving FDA clearance for TriNav AdvanceNNincreases after raising its outlook for FY26IonQhigher after the company said it successfully tested the first real-time quantum error decoderVoyager Technologiesfalls after offering to sell $350M in senior notesInnovAgedeclines after announcing a 10M share offering5. EARNINGS/GUIDANCE:Espeyreported Q4 results, with EPS and revenue lower year-over-yearPaychexreported Q1 results and provided guidance for FY27Alkamireaffirmed its outlook for FY26Guardforce AIreported results for 1H of FY26Cintasreported Q1 results and raised its outlook for FY27INDEXES:Near midday, the Dow was down 316.12, or 0.61%, to 51,547.57, the Nasdaq was down 270.34, or 0.99%, to 26,973.94, and the S&P 500 was down 48.28, or 0.62%, to 7,716.36.

TriSalus Receives FDA Clearance for TriNav Advance Device

TriSalus Life Sciences announced it has received U.S. Food and Drug Administration 510(k) clearance for TriNav Advance, the newest addition to its Pressure-Enabled Drug Delivery portfolio. TriNav Advance expands TriSalus' portfolio of PEDD devices, adding access to small, distal vessels, via a compatible delivery microcatheter, while preserving PEDD's enhanced therapeutic delivery and off-target protection. Interventional radiologists can now pair TriNav Advance with a compatible microcatheter of their choice, giving them flexibility across a broader range of procedures and anatomies. With this addition, TriSalus offers a complete portfolio addressing liver-directed therapy cases and its indication supports a broader range of embolization procedures beyond the liver. The company intends to initiate a limited market release of the TriNav Advance device over the coming weeks. "TriNav(R) Advance enhances our Pressure-Enabled Drug Delivery(TM) portfolio in support of the full range of liver embolization procedures," said Mary Szela, President and Chief Executive Officer of TriSalus. "We are proud of the range of tools we offer to physicians and believe TriNav Advance will catalyze further adoption across these procedures. We're excited to broaden our portfolio in a way that can meaningfully benefit both physicians and patients."